NasdaqCM - Delayed Quote USD

Catalyst Pharmaceuticals, Inc. (CPRX)

14.68 -0.44 (-2.91%)
At close: April 25 at 4:00 PM EDT
14.60 -0.08 (-0.54%)
Pre-Market: 8:07 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
398,204.00
398,204.00
214,203.00
140,833.00
119,073.00
Cost of Revenue
51,967.00
51,967.00
34,393.00
21,884.00
17,039.00
Gross Profit
346,237.00
346,237.00
179,810.00
118,949.00
102,034.00
Operating Expense
259,425.00
259,425.00
77,972.00
66,564.00
60,731.00
Operating Income
86,812.00
86,812.00
101,838.00
52,385.00
41,303.00
Other Income Expense
7,699.00
7,699.00
2,881.00
282.00
587.00
Pretax Income
94,511.00
94,511.00
104,719.00
52,667.00
41,890.00
Tax Provision
23,101.00
23,101.00
21,640.00
13,185.00
-33,093.00
Net Income Common Stockholders
71,410.00
71,410.00
83,079.00
39,482.00
74,983.00
Diluted NI Available to Com Stockholders
71,410.00
71,410.00
83,079.00
39,482.00
74,983.00
Basic EPS
0.67
0.67
0.80
0.38
0.72
Diluted EPS
0.63
0.63
0.75
0.37
0.71
Basic Average Shares
106,279.74
106,279.74
103,374.61
103,379.35
103,512.91
Diluted Average Shares
113,753.15
113,753.15
111,375.63
107,795.59
106,242.27
Total Operating Income as Reported
86,812.00
86,812.00
101,838.00
52,385.00
41,303.00
Total Expenses
311,392.00
311,392.00
112,365.00
88,448.00
77,770.00
Net Income from Continuing & Discontinued Operation
71,410.00
71,410.00
83,079.00
39,482.00
74,983.00
Normalized Income
71,410.00
71,410.00
83,079.00
39,482.00
74,983.00
EBIT
86,812.00
86,812.00
101,838.00
52,385.00
41,303.00
EBITDA
119,693.00
119,693.00
103,077.00
52,577.00
41,395.00
Reconciled Cost of Revenue
51,651.00
51,651.00
34,252.00
21,692.00
17,039.00
Reconciled Depreciation
32,881.00
32,881.00
1,239.00
192.00
92.00
Net Income from Continuing Operation Net Minority Interest
71,410.00
71,410.00
83,079.00
39,482.00
74,983.00
Normalized EBITDA
119,693.00
119,693.00
103,077.00
52,577.00
41,395.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 11/8/2006

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AXSM Axsome Therapeutics, Inc.
71.52
+0.49%
 
DAWN Day One Biopharmaceuticals, Inc.
13.21
-13.03%
 
ARDX Ardelyx, Inc.
6.31
-1.87%
 
HALO Halozyme Therapeutics, Inc.
38.46
-1.69%
 
XFOR X4 Pharmaceuticals, Inc.
1.1300
-12.40%
 
LGND Ligand Pharmaceuticals Incorporated
70.37
-0.89%
 
EWTX Edgewise Therapeutics, Inc.
15.94
-1.06%
 
AUPH Aurinia Pharmaceuticals Inc.
4.8700
-3.18%
 
OCUP Ocuphire Pharma, Inc.
1.5350
+0.33%
 
VNDA Vanda Pharmaceuticals Inc.
4.4800
-1.75%